Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04750824 · ClinicalTrials.gov registry record
Real-World Effectiveness of Afatinib (Gilotrif) Following Immunotherapy in the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: A Multi-Site Retrospective Chart Review Study in the U.S.
A clinical trial of Non-squamous Non-small Cell Lung Cancer, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- 110
- Enrollment target
- 1
- Study location
NCT04750824: Completed study of Non-squamous Non-small Cell Lung Cancer, sponsored by Boehringer Ingelheim.
NCT04750824 is a study of Non-squamous Non-small Cell Lung Cancer that has completed, run by Boehringer Ingelheim. The registered enrollment target is 110 participants, below the 386-participant average among 9 other Non-squamous Non-small Cell Lung Cancer trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04750824, a study of Non-squamous Non-small Cell Lung Cancer, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- 110 participants
- Enrollment target
- 1
- Study location
Study Summary
Characteristics of patients with Neuregulin-1 (NRG1) gene fusion-positive solid tumors treated with afatinib, and characteristics of those treated with another systemic therapy.
Primary Outcome
ORR was defined as the percentage of patients with a complete response (CR) or partial response (PR) out of all patients (CR+PR/all patients) at initial response assessment and best response (response based on the scan where the patient showed the best response to treatment (not progression)). Charted/physician-reported (physician-provided information as recorded in patient's chart) ORR is reported.
Conditions Studied
Interventions
- DRUG Afatinib
- DRUG other systemic therapy
Study Locations (1)
Ohio
- Cardinal Health - Dublin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2020-10-15 |
| Est. Completion | 2021-12-20 |
What the finished NCT04750824 record still lists
NCT04750824 is an observational study that tracks outcomes without assigning an intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, below the 386-participant average among 9 other Non-squamous Non-small Cell Lung Cancer trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Non-squamous Non-small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Afatinib is the first listed.
NCT04750824 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT04750824 about?
NCT04750824 is a clinical study titled "Real-World Effectiveness of Afatinib (Gilotrif) Following Immunotherapy in the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: A Multi-Site Retrospective Chart Review Study in the U.S.". Characteristics of patients with Neuregulin-1 (NRG1) gene fusion-positive solid tumors treated with afatinib, and characteristics of those treated with another systemic therapy.
What is the current status of trial NCT04750824?
This trial is currently completed. The enrollment target is 110 participants. The study started on 2020-10-15. Estimated completion is 2021-12-20.
What conditions does trial NCT04750824 study?
This clinical trial studies the following conditions: Non-squamous Non-small Cell Lung Cancer.
What interventions are being tested in trial NCT04750824?
The interventions under investigation include: Afatinib (DRUG), other systemic therapy (DRUG).
Who is sponsoring clinical trial NCT04750824?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04750824 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-squamous Non-small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04750824's enrollment target sits among peer trials
110 7th of 9 higher than 3 of 9 other Non-squamous Non-small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-squamous Non-small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
RECRUITING · Phase 3
-
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 2
-
Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC
ACTIVE NOT RECRUITING · Phase 2
-
Phase III Study of AK112 for NSCLC Patients
ACTIVE NOT RECRUITING · Phase 3
-
Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer
ACTIVE NOT RECRUITING · Phase 2
-
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI